The Supreme Court in Myriad Genetics overturned decades of USPTO practice and arguably US caselaw regarding the patenting of DNA. At issue in the case were patent rights to BRCA genes, associated with hereditary forms of breast cancer, and women’s right to control their own genes. Current impacts of the Supreme Court’s decision on women's health and patent practice will be discussed.
Speaker Bio: Valerie Neymeyer-Tynkov has practiced in the chemical patent field for over 15 years. She attended the Chicago-Kent College of Law in downtown Chicago, and later served as an Adjunct Professor there. Her interest in the Myriad Genetics case series and its progeny stems in large part from the courts’ consideration of moral factors in patent monopolies.
Date: October 15 at noon CLE offered: yes Credits: 1 hour (estimated)
Where: Amin Talati Wasserman LLP 100 S Wacker Dr #2000 Chicago, IL 60606
There is no cost to attend this event. However, space is limited so please RSVP to Angela Kalsi at Angela@amintalati.com.